Cardinal Capital Management cut its position in Eli Lilly and Co. (NYSE:LLY) by 0.1% during the second quarter, Holdings Channel reports. The institutional investor owned 44,882 shares of the company’s stock after selling 55 shares during the period. Eli Lilly and makes up approximately 1.4% of Cardinal Capital Management’s portfolio, making the stock its 29th largest position. Cardinal Capital Management’s holdings in Eli Lilly and were worth $3,534,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. BlackRock Fund Advisors boosted its position in Eli Lilly and by 1.0% in the first quarter. BlackRock Fund Advisors now owns 16,731,379 shares of the company’s stock worth $1,204,827,000 after buying an additional 159,487 shares during the last quarter. Franklin Resources Inc. boosted its position in Eli Lilly and by 3.6% in the first quarter. Franklin Resources Inc. now owns 27,744,978 shares of the company’s stock worth $1,997,920,000 after buying an additional 961,204 shares during the last quarter. FDO Partners LLC boosted its position in Eli Lilly and by 8.8% in the first quarter. FDO Partners LLC now owns 9,314 shares of the company’s stock worth $671,000 after buying an additional 751 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in Eli Lilly and by 11.6% in the first quarter. Rehmann Capital Advisory Group now owns 5,417 shares of the company’s stock worth $390,000 after buying an additional 563 shares during the last quarter. Finally, Stratos Wealth Partners LTD. boosted its position in Eli Lilly and by 10.7% in the first quarter. Stratos Wealth Partners LTD. now owns 6,731 shares of the company’s stock worth $485,000 after buying an additional 653 shares during the last quarter. Institutional investors and hedge funds own 74.96% of the company’s stock.
Eli Lilly and Co. (NYSE:LLY) traded down 0.34% on Thursday, reaching $81.47. The company had a trading volume of 2,994,223 shares. The company has a market capitalization of $86.17 billion, a P/E ratio of 35.12 and a beta of 0.17. Eli Lilly and Co. has a 52 week low of $67.88 and a 52 week high of $88.16. The stock’s 50-day moving average is $79.34 and its 200-day moving average is $77.38.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. During the same quarter in the previous year, the business earned $0.90 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Co. will post $3.59 EPS for the current fiscal year.
Several equities research analysts recently weighed in on the company. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a report on Wednesday. BMO Capital Markets restated a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a report on Monday. Goldman Sachs Group Inc. upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and increased their target price for the company from $89.00 to $95.00 in a report on Tuesday, September 27th. Deutsche Bank AG restated a “buy” rating on shares of Eli Lilly and in a report on Tuesday, September 20th. Finally, Jefferies Group restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Wednesday, September 14th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Buy” and a consensus price target of $97.16.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $83.16, for a total transaction of $100,873.08. Following the completion of the transaction, the insider now owns 1,300 shares in the company, valued at $108,108. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The shares were sold at an average price of $79.54, for a total value of $16,703,400.00. Following the transaction, the insider now owns 126,220,804 shares of the company’s stock, valued at approximately $10,039,602,750.16. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.